ADMA Biologics AI Stock Analysis
Want to see ADMA full AI Analyst Report?
ADMA Biologics (ADMA) AI Stock Analysis
ADMA Biologics
(NASDAQ:ADMA)
The score is driven primarily by strong financial performance (high margins and robust operating/free cash flow) and a constructive earnings update with raised profitability guidance and ongoing share repurchases. Technicals support the trend, but near-overbought RSI adds short-term risk. Valuation is reasonable at a 16.721 P/E, while leverage and working-capital (DSO) pressure remain the key offsets.
ADMA Biologics (ADMA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.19M
- Price to Earnings (P/E)
- 17.1
- Beta (1Y)
- 0.71
- Revenue Growth
- 6.26%
- EPS Growth
- -10.51%
- Country
- US
- Employees
- 644
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ADMA Biologics Business Overview & Revenue Model
Company Description
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune...
How the Company Makes Money
ADMA primarily makes money by selling plasma-derived therapeutic products to healthcare providers and channel partners. Its key revenue stream is product sales of immune globulin (IG) therapies and other plasma-derived biologics that are manufactured...
ADMA Biologics Earnings Call Summary
The call was strongly positive overall. ASCENIV delivered accelerating revenue growth, expanded margins, substantial earnings and cash-flow growth, and durable patient-demand indicators. The company raised minimum adjusted EBITDA and adjusted net income guidance, continued significant share repurchases, and reported constructive FDA feedback for SG-001. The main challenges were BIVIGAM's revenue decline, persistent pricing and competitive pressure in the standard IG market, moderate secondary immunodeficiency growth, and DSOs remaining above the target range.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated full year 2026 revenue guidance of at least $530 million, increased minimum adjusted EBITDA guidance to at least $275 million from $265 million previously, and increased minimum adjusted net income guidance to at least $180 million from $170 million previously; it continues to execute against a target of $200 million or more in total share repurchases during 2026. Management said ASCENIV month-to-month growth remains within the previously stated 2% to 4% growth expectation and estimated full-year growth at about 25%, maybe a little more than that, while SG-001 represents a potential $300 million to $500 million annual revenue opportunity. The DSO target remains between 90 to 105 days, Q4 R&D spend is expected to be probably close to $10 million, and management expects to provide firm clinical timelines sometime next year.
ADMA Biologics Financial Statement Overview
Summary
Strong turnaround with TTM revenue of $519.2M, high gross margin (~68.5%) and net margin (~35.1%), plus solid cash generation (TTM operating cash flow ~$140.8M; free cash flow ~$132.9M with good conversion vs. net income). Offsets are higher leverage versus last year (TTM debt ~$202.8M; debt-to-equity ~0.46) and historical volatility in growth and cash-flow consistency.
Income Statement
86Very PositiveBalance Sheet
68PositiveCash Flow
79Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 519.15M | 510.17M | 426.45M | 258.21M | 154.08M | 80.94M |
| Gross Profit | 355.76M | 292.76M | 219.55M | 88.94M | 35.27M | 1.17M |
| EBITDA | 252.60M | 197.86M | 147.69M | 5.12M | -39.51M | -53.10M |
| Net Income | 182.41M | 146.93M | 197.67M | -28.24M | -65.90M | -71.65M |
Balance Sheet | ||||||
| Total Assets | 732.49M | 624.24M | 488.68M | 329.18M | 348.46M | 276.25M |
| Cash, Cash Equivalents and Short-Term Investments | 124.56M | 87.63M | 103.15M | 51.35M | 86.52M | 51.09M |
| Total Debt | 202.80M | 79.89M | 82.12M | 141.42M | 154.44M | 102.92M |
| Total Liabilities | 293.98M | 146.92M | 139.66M | 193.98M | 196.49M | 135.08M |
| Stockholders Equity | 438.51M | 477.32M | 349.02M | 135.21M | 151.97M | 141.17M |
Cash Flow | ||||||
| Free Cash Flow | 132.91M | 27.82M | 110.10M | 3.82M | -73.42M | -125.88M |
| Operating Cash Flow | 140.79M | 50.40M | 118.67M | 8.80M | -59.51M | -112.37M |
| Investing Cash Flow | -2.20M | -21.89M | -8.57M | -4.98M | -13.91M | -13.51M |
| Financing Cash Flow | -75.43M | -44.02M | -58.30M | -38.99M | 108.85M | 121.05M |
ADMA Biologics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMA, the sentiment is Positive. The current price of 13.63 is above the 20-day moving average (MA) of 12.03, above the 50-day MA of 10.73, and above the 200-day MA of 10.69, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 69.13 is Neutral, neither overbought nor oversold. The STOCH value of 85.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADMA.
ADMA Biologics Risk Analysis
ADMA Biologics disclosed 59 risk factors in its most recent earnings report. ADMA Biologics reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksADMA Biologics Peers Comparison
Overall Rating
AUPH84Outperform
RIGL79Outperform
ADMA77Outperform
PHAR74Outperform
OMER50Neutral
BCRX49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $2.06B | 6.45 | 51.92% | ― | 21.04% | 312.89% | |
| 79Outperform | $808.18M | 2.53 | 73.94% | ― | 2.18% | 165.65% | |
| 77Outperform | $3.02B | 17.07 | 42.56% | ― | 6.26% | -10.51% | |
| 74Outperform | $872.71M | 35.07 | 8.96% | ― | 6.67% | 2242.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.04B | 8.78 | -120.76% | ― | ― | ― | |
| 49Neutral | $1.93B | -5.52 | 94.36% | ― | 60.30% | -3028.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ADMA | ADMA Biologics Inc | 13.63 | -2.32 | -14.55% | |
| BCRX | BioCryst Pharmaceuticals | 7.50 | 0.57 | 8.23% | |
| OMER | Omeros Corporation | 13.92 | 5.70 | 69.34% | |
| RIGL | Rigel Pharmaceuticals | 42.92 | 1.24 | 2.98% | |
| AUPH | Aurinia Pharmaceuticals | 15.40 | 0.20 | 1.32% | |
| PHAR | Pharming Group Nv | 12.06 | -4.05 | -25.14% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
